Syed Mohi Ahmed, MD, PhD
@smohahm.bsky.social
Medical Oncologist, follows GU, lung, head and neck and gastroesophageal cancers on BlueSky
Medical Director, Northwestern Medicine Oak Brook Cancer Center. Views are personal
Reposted by Syed Mohi Ahmed, MD, PhD
3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc
𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa
𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer | NEJM
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically r...
nej.md
October 31, 2025 at 3:08 PM
3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc
𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa
𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa